Home
>
US Stocks
>
Dynavax Technologies Corp.
Dynavax Technologies Corp.
DVAX

Dynavax Technologies Corp.

$17.142.34%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
17.46
Today Low/High
16.9 / 17.68
52 Week Low/High
$3.58 / $13.87
P/E ratio
-230.836
Market Cap
$1.41B

Company Details

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.
Organisation
Dynavax Technologies Corp.
Headquaters
Emeryville, California, US
Employees
245
Industry
Health Technology
CEO
Ryan Spencer

Discover more

Frequently Asked Questions

What is Dynavax Technologies Corp. share price today

Can Indians buy Dynavax Technologies Corp. shares?

How can I buy Dynavax Technologies Corp. shares from India?

Can Fractional shares of Dynavax Technologies Corp. be purchased?

What are the documents required to start investing in Dynavax Technologies Corp. stocks?

We are a SEBI registered investement advisor